Stephen B Williams1, Jinhai Huo2, Yiyi Chu3, Jacques G Baillargeon4, Timothy Daskivich5, Yong-Fang Kuo6, Christopher D Kosarek7, Simon P Kim8, Eduardo Orihuela7, Douglas S Tyler9, Stephen J Freedland4, Ashish M Kamat10. 1. Division of Urology, The University of Texas Medical Branch at Galveston, Galveston, TX. Electronic address: stbwilli@utmb.edu. 2. Department of Health Services Research, Management and Policy, The University of Florida, Gainesville, FL. 3. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Medicine, Division of Epidemiology, Sealy Center on Aging, The University of Texas Medical Branch at Galveston, Galveston, TX. 5. Department of Urology, Cedars Sinai Medical Center, Los Angeles, CA. 6. Department of Medicine, Division of Biostatistics, Sealy Center on Aging, Sealy Center on Aging, The University of Texas Medical Branch at Galveston, Galveston, TX. 7. Division of Urology, The University of Texas Medical Branch at Galveston, Galveston, TX. 8. Urology Institute, Center for Health Care Quality and Outcomes, University Hospitals Case Western Medical Center, Case Western Reserve University, Cleveland, OH; Cancer Outcomes and Public Policy Effectiveness Research Center, Yale University, New Haven, CT. 9. Department of Surgery, The University of Texas Medical Branch at Galveston, Galveston, TX. 10. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
OBJECTIVE: To develop and validate a nomogram assessing cancer and all-cause mortality following radical cystectomy. Given concerns regarding the morbidity associated with surgery, there is a need for incorporation of cancer-specific and competing risks into patient counseling and recommendations. MATERIALS AND METHODS: A total of 5325 and 1257 diagnosed with clinical stage T2-T4a muscle-invasive bladder cancer from January 1, 2006 to December 31, 2011 from Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked data, respectively. Cox proportional hazards models were used and a nomogram was developed to predict 3- and 5-year overall and cancer-specific survival with external validation. RESULTS: Patients who underwent radical cystectomy were mostly younger, male, married, non-Hispanic white and had fewer comorbidities than those who did not undergo radical cystectomy (P < .001). Married patients, in comparison with their unmarried counterparts, had both improved overall (hazard ratio 0.76; 95% confidence interval 0.70-0.83, P < .001) and cancer-specific (hazard ratio 0.76; 95% confidence interval 0.68-0.85, P < .001) survival. A nomogram developed using Surveillance, Epidemiology, and End Results-Medicare data, predicted 3- and 5-year overall and cancer-specific survival rates with concordance indices of 0.65 and 0.66 in the validated Texas Cancer Registry-Medicare cohort, respectively. CONCLUSION: Older, unmarried patients with increased comorbidities are less likely to undergo radical cystectomy. We developed and validated a generalizable instrument that has been converted into an online tool (Radical Cystectomy Survival Calculator), to provide a benefit-risk assessment for patients considering radical cystectomy.
OBJECTIVE: To develop and validate a nomogram assessing cancer and all-cause mortality following radical cystectomy. Given concerns regarding the morbidity associated with surgery, there is a need for incorporation of cancer-specific and competing risks into patient counseling and recommendations. MATERIALS AND METHODS: A total of 5325 and 1257 diagnosed with clinical stage T2-T4a muscle-invasive bladder cancer from January 1, 2006 to December 31, 2011 from Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked data, respectively. Cox proportional hazards models were used and a nomogram was developed to predict 3- and 5-year overall and cancer-specific survival with external validation. RESULTS:Patients who underwent radical cystectomy were mostly younger, male, married, non-Hispanic white and had fewer comorbidities than those who did not undergo radical cystectomy (P < .001). Married patients, in comparison with their unmarried counterparts, had both improved overall (hazard ratio 0.76; 95% confidence interval 0.70-0.83, P < .001) and cancer-specific (hazard ratio 0.76; 95% confidence interval 0.68-0.85, P < .001) survival. A nomogram developed using Surveillance, Epidemiology, and End Results-Medicare data, predicted 3- and 5-year overall and cancer-specific survival rates with concordance indices of 0.65 and 0.66 in the validated Texas Cancer Registry-Medicare cohort, respectively. CONCLUSION: Older, unmarried patients with increased comorbidities are less likely to undergo radical cystectomy. We developed and validated a generalizable instrument that has been converted into an online tool (Radical Cystectomy Survival Calculator), to provide a benefit-risk assessment for patients considering radical cystectomy.
Authors: Jennifer M Taylor; Andrew Feifer; Caroline J Savage; Alexandra C Maschino; Melanie Bernstein; Harry W Herr; S Machele Donat Journal: BJU Int Date: 2011-07-01 Impact factor: 5.588
Authors: Hannah K Weir; Christopher J Johnson; Angela B Mariotto; Donna Turner; Reda J Wilson; Diane Nishri; Kevin C Ward Journal: J Natl Cancer Inst Monogr Date: 2014-11
Authors: Stephen A Boorjian; Simon P Kim; Matthew K Tollefson; Alonso Carrasco; John C Cheville; R Houston Thompson; Prabin Thapa; Igor Frank Journal: J Urol Date: 2013-01-09 Impact factor: 7.450
Authors: Georgios Gakis; Jason Efstathiou; Seth P Lerner; Michael S Cookson; Kirk A Keegan; Khurshid A Guru; William U Shipley; Axel Heidenreich; Mark P Schoenberg; Arthur I Sagaloswky; Mark S Soloway; Arnulf Stenzl Journal: Eur Urol Date: 2012-08-14 Impact factor: 20.096
Authors: Stephen H Culp; Rian J Dickstein; H Barton Grossman; Shanna M Pretzsch; Sima Porten; Siamak Daneshmand; Jie Cai; Susan Groshen; Arlene Siefker-Radtke; Randall E Millikan; Bogdan Czerniak; Neema Navai; Matthew F Wszolek; Ashish M Kamat; Colin P N Dinney Journal: J Urol Date: 2013-07-30 Impact factor: 7.450
Authors: Timur Mitin; Asha George; Anthony L Zietman; Niall M Heney; Donald S Kaufman; Robert G Uzzo; Robert Dreicer; H James Wallace; Luis Souhami; M Chris Dobelbower; Howard M Sandler; William U Shipley Journal: Int J Radiat Oncol Biol Phys Date: 2015-09-28 Impact factor: 7.038
Authors: Stephen B Williams; Yong Shan; Usama Jazzar; Hemalkumar B Mehta; Jacques G Baillargeon; Jinhai Huo; Anthony J Senagore; Eduardo Orihuela; Douglas S Tyler; Todd A Swanson; Ashish M Kamat Journal: JAMA Surg Date: 2018-10-01 Impact factor: 14.766
Authors: Diana Magee; Douglas Cheung; Amanda Hird; Srikala S Sridhar; Charles Catton; Peter Chung; Alejandro Berlin; Padraig Warde; Alexandre Zlotta; Neil Fleshner; Girish S Kulkarni Journal: Can Urol Assoc J Date: 2022-04 Impact factor: 2.052
Authors: Jeffrey J Leow; Jens Bedke; Karim Chamie; Justin W Collins; Siamak Daneshmand; Petros Grivas; Axel Heidenreich; Edward M Messing; Trevor J Royce; Alexander I Sankin; Mark P Schoenberg; William U Shipley; Arnauld Villers; Jason A Efstathiou; Joaquim Bellmunt; Arnulf Stenzl Journal: World J Urol Date: 2019-01-25 Impact factor: 4.226
Authors: Stephen B Williams; Ashish M Kamat; Karim Chamie; Michael Froehner; Manfred P Wirth; Peter N Wiklund; Peter C Black; Gary D Steinberg; Stephen A Boorjian; Sia Daneshmand; Peter J Goebell; Kamal S Pohar; Shahrokh F Shariat; George N Thalmann Journal: Eur Urol Oncol Date: 2018-06-06
Authors: Michael Froehner; Rainer Koch; Matthias Hübler; Ulrike Heberling; Vladimir Novotny; Stefan Zastrow; Oliver W Hakenberg; Manfred P Wirth Journal: BMC Urol Date: 2018-10-22 Impact factor: 2.264